Onyx Scientific is the CDMO division of Ipca Laboratories, offering small molecule drug substance development and manufacturing services. Our MHRA-licensed sites in the UK offer early development of candidate APIs and manufacturing for clinical phases through to commercial supply. Dedicated solid-state and analytical chemistry teams expedite development activities at Onyx but are also available to provide full-service outsourced projects to complement or support your in-house campaigns. With a wealth of early development experience and success, our pragmatic, fit-for-purpose approach focuses on rapid process development and a view to future GMP campaigns. Where required, scale-up through Phase II towards commercial manufacture is retained either at Onyx or within the Group through transfer to our sister sites and colleagues in the USA and India.